Leukemia - Table of Contents alert Volume 31 Issue 7

If you are unable to see the message below, click here to view.

Advertisement Leukemia: Collection on Acute Myeloid Leukemia AML is an area of focus for Leukemia and this collection brings together a number of recent key articles published in the journal.  Access this collection free online for six months Funded by a grant from Astex Pharmaceuticals, Inc. (a member of the Otsuka group) TABLE OF CONTENTS Volume 31, Issue 7 (July 2017) In this issue Editorial Review Original Articles Letters To The Editor Corrigenda Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Celebrating 30 years of Leukemia — 1987 to 2017 Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone. Watch our anniversary video showing a brief impact overview >>>   Editorial Top Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations OPEN R Rosenquist, P Ghia, A Hadzidimitriou, L-A Sutton, A Agathangelidis, P Baliakas, N Darzentas, V Giudicelli, M-P Lefranc, A W Langerak, C Belessi, F Davi and K Stamatopoulos ERIC, the European Research Initiative on CLL Leukemia 2017 31: 1477-1481; advance online publication, April 25, 2017; 10.1038/leu.2017.125 Full Text Review Top Measurable residual disease testing in acute myeloid leukaemia C S Hourigan, R P Gale, N J Gormley, G J Ossenkoppele and R B Walter Leukemia 2017 31: 1482-1490; advance online publication, April 7, 2017; 10.1038/leu.2017.113 Abstract | Full Text Original Articles Top ACUTE LYMPHOBLASTIC LEUKEMIA Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia OPEN C Vesely, C Frech, C Eckert, G Cario, A Mecklenbräuker, U zur Stadt, K Nebral, F Kraler, S Fischer, A Attarbaschi, M Schuster, C Bock, H Cavé, A von Stackelberg, M Schrappe, M A Horstmann, G Mann, O A Haas and R Panzer-Grümayer Leukemia 2017 31: 1491-1501; advance online publication, November 30, 2016; 10.1038/leu.2016.365 Abstract | Full Text CHRONIC MYELOGENOUS LEUKEMIA Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics OPEN S Reckel, R Hamelin, S Georgeon, F Armand, Q Jolliet, D Chiappe, M Moniatte and O Hantschel Leukemia 2017 31: 1502-1512; advance online publication, January 23, 2017; 10.1038/leu.2017.36 Abstract | Full Text Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis J A Cutler, R Tahir, S K Sreenivasamurthy, C Mitchell, S Renuse, R S Nirujogi, A H Patil, M Heydarian, X Wong, X Wu, T-C Huang, M-S Kim, K L Reddy and A Pandey Leukemia 2017 31: 1513-1524; advance online publication, February 17, 2017; 10.1038/leu.2017.61 Abstract | Full Text Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study OPEN A Hochhaus, T Masszi, F J Giles, J P Radich, D M Ross, M T Gómez Casares, A Hellmann, J Stentoft, E Conneally, V García-Gutiérrez, N Gattermann, W Wiktor-Jedrzejczak, P D le Coutre, B Martino, S Saussele, H D Menssen, W Deng, N Krunic, V Bedoucha and G Saglio Leukemia 2017 31: 1525-1531; advance online publication, February 20, 2017; 10.1038/leu.2017.63 Abstract | Full Text Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia S H Han, S-H Kim, H-J Kim, Y Lee, S-Y Choi, G Park, D-H Kim, A Lee, J Kim, J-M Choi, Y Kim, K Myung, H Kim and D-W Kim Leukemia 2017 31: 1532-1539; advance online publication, February 24, 2017; 10.1038/leu.2017.72 Abstract | Full Text Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis K Hussein, A Stucki-Koch, G Göhring, H Kreipe and M Suttorp Leukemia 2017 31: 1540-1546; advance online publication, February 27, 2017; 10.1038/leu.2017.73 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, L-A Sutton, S J Blakemore, J Galan-Sousa, K Plevova, P Baliakas, D Rossi, R Clifford, D Roos-Weil, V Navrkalova, B Dörken, C A Schmitt, K E Smedby, G Juliusson, B Giacopelli, J S Blachly, C Belessi, P Panagiotidis, N Chiorazzi, F Davi, A W Langerak, D Oscier, A Schuh, G Gaidano, P Ghia, W Xu, L Fan, O A Bernard, F Nguyen-Khac, L Rassenti, J Li, T J Kipps, K Stamatopoulos, S Pospisilova, T Zenz, C C Oakes, J C Strefford, R Rosenquist and F Damm Leukemia 2017 31: 1547-1554; advance online publication, November 28, 2016; 10.1038/leu.2016.359 Abstract | Full Text Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements A Vardi, E Vlachonikola, M Karypidou, E Stalika, V Bikos, K Gemenetzi, C Maramis, A Siorenta, A Anagnostopoulos, S Pospisilova, N Maglaveras, I Chouvarda, K Stamatopoulos and A Hadzidimitriou Leukemia 2017 31: 1555-1561; advance online publication, November 25, 2016; 10.1038/leu.2016.362 Abstract | Full Text MULTIPLE MYELOMA, GAMMOPATHIES Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category E Muchtar, A Dispenzieri, S K Kumar, R P Ketterling, D Dingli, M Q Lacy, F K Buadi, S R Hayman, P Kapoor, N Leung, R Chakraborty, W Gonsalves, R Warsame, T V Kourelis, S Russell, J A Lust, Y Lin, R S Go, S Zeldenrust, R A Kyle, S V Rajkumar and M A Gertz Leukemia 2017 31: 1562-1569; advance online publication, December 1, 2016; 10.1038/leu.2016.369 Abstract | Full Text The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment F Fan, M H Bashari, E Morelli, G Tonon, S Malvestiti, S Vallet, M Jarahian, A Seckinger, D Hose, L Bakiri, C Sun, Y Hu, C R Ball, H Glimm, M Sattler, H Goldschmidt, E F Wagner, P Tassone, D Jaeger and K Podar Leukemia 2017 31: 1570-1581; advance online publication, November 28, 2016; 10.1038/leu.2016.358 Abstract | Full Text STEM CELL TRANSPLANTATION Extended time-lapse in vivo imaging of tibia bone marrow to visualize dynamic hematopoietic stem cell engraftment S Kim, L Lin, G A J Brown, K Hosaka and E W Scott Leukemia 2017 31: 1582-1592; advance online publication, November 28, 2016; 10.1038/leu.2016.354 Abstract | Full Text MOLECULAR TARGETS FOR THERAPY Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells H Ding, K L Peterson, C Correia, B Koh, P A Schneider, G S Nowakowski and S H Kaufmann Leukemia 2017 31: 1593-1602; advance online publication, November 28, 2016; 10.1038/leu.2016.357 Abstract | Full Text IMMUNOTHERAPY Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling OPEN S T Ribeiro, M Tesio, J C Ribot, E Macintyre, J T Barata and B Silva-Santos Leukemia 2017 31: 1603-1610; advance online publication, November 30, 2016; 10.1038/leu.2016.363 Abstract | Full Text A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells OPEN E J Cheadle, G Lipowska-Bhalla, S J Dovedi, E Fagnano, C Klein, J Honeychurch and T M Illidge Leukemia 2017 31: 1611-1621; advance online publication, November 28, 2017; 10.1038/leu.2016.352 Abstract | Full Text Letters To The Editor Top Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia OPEN C Anadón, G van Tetering, H J Ferreira, C Moutinho, A Martínez-Cardús, A Villanueva, M Soler, H Heyn, S Moran, M Castro de Moura, F Setien, A Vidal, E Genescà, J M Ribera, J F Nomdedeu, S Guil and M Esteller Leukemia 2017 31: 1622-1625; advance online publication, March 27, 2017; 10.1038/leu.2017.99 Full Text Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1 A Cosson, E Chapiro, N Bougacha, J Lambert, L Herbi, H-A Cung, C Algrin, B Keren, F Damm, C Gabillaud, M-N Brunelle-Navas, F Davi, H Merle-Béral, M Le Garff-Tavernier, D Roos-Weil, S Choquet, M Uzunov, V Morel, V Leblond, K Maloum, S Lepretre, P Feugier, C Lesty, J Lejeune, L Sutton, Y Landesman, S A Susin and F Nguyen-Khac Leukemia 2017 31: 1625-1629; advance online publication, March 27, 2017; 10.1038/leu.2017.100 Full Text Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm K Suzuki, Y Suzuki, A Hama, H Muramatsu, M Nakatochi, M Gunji, D Ichikawa, M Hamada, R Taniguchi, S Kataoka, N Murakami, D Kojima, Y Sekiya, E Nishikawa, N Kawashima, A Narita, N Nishio, Y Nakazawa, H Iwafuchi, K-i Watanabe, Y Takahashi, M Ito, S Kojima, S Kato and Y Okuno Leukemia 2017 31: 1629-1633; advance online publication, March 27, 2017; 10.1038/leu.2017.101 Full Text PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma V Atsaves, N Tsesmetzis, D Chioureas, L Kis, V Leventaki, E Drakos, T Panaretakis, D Grander, L J Medeiros, K H Young and G Z Rassidakis Leukemia 2017 31: 1633-1637; advance online publication, March 27, 2017; 10.1038/leu.2017.103 Full Text Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient S Herold, M Kuhn, M v Bonin, T Stange, U Platzbecker, J Radke, T Lange, K Sockel, K Gutsche, J Schetelig, C Röllig, C Schuster, I Roeder, A Dahl, B Mohr, H Serve, C Brandts, G Ehninger, M Bornhäuser and C Thiede Leukemia 2017 31: 1637-1640; advance online publication, March 28, 2017; 10.1038/leu.2017.104 Full Text Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape P Silva, M Neumann, M P Schroeder, S Vosberg, C Schlee, K Isaakidis, J Ortiz-Tanchez, L R Fransecky, T Hartung, S Türkmen, A Graf, S Krebs, H Blum, C Müller-Tidow, C Thiede, G Ehninger, H Serve, J Hecht, W E Berdel, P A Greif, C Röllig and C D Baldus Leukemia 2017 31: 1640-1644; advance online publication, April 3, 2017; 10.1038/leu.2017.109 Full Text PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment D Jones, J A Woyach, W Zhao, S Caruthers, H Tu, J Coleman, J C Byrd, A J Johnson and G Lozanski Leukemia 2017 31: 1645-1647; advance online publication, April 3, 2017; 10.1038/leu.2017.110 Full Text NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma OPEN M Hao, R Franqui-Machin, H Xu, J Shaughnessy, Jr, B Barlogie, D Roodman, D E Quelle, S Janz, M H Tomasson, R D Sanderson, L Qiu, I Frech, G Tricot and F Zhan Leukemia 2017 31: 1648-1650; advance online publication, April 12, 2017; 10.1038/leu.2017.115 Full Text Tunneling nanotubes facilitate autophagosome transfer in the leukemic niche OPEN B de Rooij, R Polak, F Stalpers, R Pieters and M L den Boer Leukemia 2017 31: 1651-1654; advance online publication, April 12, 2017; 10.1038/leu.2017.117 Full Text Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors P Kongtim, K Adekola, D R Milton, R Ramlal, A Jimenez, J Chen, G Rondon, S Ahmed, P Kebriaei, O Betul, C M Hosing, U Popat, I Khouri, E Jabbour, J E Cortes, H M Kantarjian, R E Champlin and S O Ciurea Leukemia 2017 31: 1654-1657; advance online publication, April 12, 2017; 10.1038/leu.2017.118 Full Text Corrigenda Top Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells W Fiskus, S Sharma, B Shah, B P Portier, S G T Devaraj, K Liu, S P Iyer, D Bearss and K N Bhalla Leukemia 2017 31: 1658; advance online publication, March 21, 2017; 10.1038/leu.2017.77 Full Text A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials G Montalban-Bravo, X Huang, K Naqvi, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian and G Garcia-Manero Leukemia 2017 31: 1659; advance online publication, March 24, 2017; 10.1038/leu.2017.85 Full Text Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome M E Varney, K Choi, L Bolanos, S Christie, J Fang, H L Grimes, J P Maciejewski, J-I Inoue and D T Starczynowski Leukemia 2017 31: 1659; advance online publication, April 7, 2017; 10.1038/leu.2017.95 Full Text Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia S H Han, S-H Kim, H-J Kim, Y Lee, S-Y Choi, G Park, D-H Kim, A Lee, J Kim, J-M Choi, Y Kim, K Myung, H Kim and D-W Kim Leukemia 2017 31: 1659; advance online publication, April 11, 2017; 10.1038/leu.2017.107 Full Text Equivalence of BCSH and WHO diagnostic criteria for ET C N Harrison, M F McMullin, A R Green and A J Mead Leukemia 2017 31: 1660; advance online publication, May 5, 2017; 10.1038/leu.2017.119 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.